



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

September 9, 2019

Allison Lucas
Siri and Glimstad, LLP
200 Park Avenue, Seventeenth Floor
New York, New York 10166
Via email: foia@sirillp.com

Dear Ms. Lucas:

This letter is regarding to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of July 30, 2019, assigned #19-01029-FOIA, for:

Each and every email communication between January 1, 2010, and December 31, 2014 which includes Kristin Pope or her email address on the "To", "From", "Cc" or "Bcc" line and also includes an email address ending in @merck.com on the "To", "From", "Cc" or "Bcc" line.

We located 169 pages of responsive records (169 pages released in full or part; no pages withheld in full). After a careful review of these pages, some information was withheld from release pursuant to 5 U.S.C. §552, Exemption (b)(6).


Exemption (b)(6) protects information in personnel and medical files and similar files when disclosure would constitute a clearly unwarranted invasion of personal privacy. The information that has been withheld under Exemption (b)(6) consists of personal information, such as conference call passcodes and personal cell phone numbers. We have determined that the individual(s) to whom this information pertains has a substantial privacy interest in withholding it.

You may contact our FOIA Public Liaison at 770-488-6277 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

If you are not satisfied with the response to this request, you may administratively appeal by writing to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue, Suite 729H, Washington, D.C. 20201. Please mark both your appeal letter and envelope "FOIA Appeal."

Your appeal must be postmarked or electronically transmitted by December 8, 2019.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', with a stylized, cursive script.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

Enclosures

19-01029-FOIA

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 24 Nov 2014 16:13:50 +0000
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: Dec. 15th CDC/Merck meeting dial information

Hi Barb,

I hope you had a nice weekend.

We will be using this bridge line for the call on December 15th: 866-736-9302; passcode 

(b)(6)

I think the agenda items you shared are good - particularly the rollout plans/timeline and coordination of messaging around potential delays and use (revaccination, interchangeability, etc). Given there is only an hour, I think leaving time for discussion will be helpful and if there are any pre-read materials you want to share we can make sure everyone has them in advance.

Hopefully there won't be any more changes with Anne's schedule! I will be out of the country on the 15th so I won't be joining the call but Candice Swartwood (copied here) will be acting Policy Director while I am away.

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 3:11 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Let's go with 4-5 on Dec 15.

Please let me know if you would like any changes made to the agenda or if there are any specific questions you would like us to address.

Have a good weekend!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Friday, November 21, 2014 12:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

I think Anne should be back in the office on 12/15, so either time should work.

This is the earliest date she has available, and hopefully there won't be any further glitches!

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 12:20 PM

To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

Thanks for the org chart – very helpful.

I am sure we can figure out how to make Dec 15 work. Please give me a day or so to see which time is better at this end. Do you think 4-5 might be better for Anne?

And I will ask the obvious – I assume there is no way we can talk during the first week of December, correct?

Thanks again!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Thursday, November 20, 2014 1:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Attached is the most recent NCIRD org chart. Let me know if you have any questions.

I know this option isn't ideal, but would either of these work for your group?

Monday, December 15th – 11am- 12pm or 4-5pm

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 8:29 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Thanks for the heads up re the date.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, November 19, 2014 7:05 PM
To: Kuter, Barbara J.
Subject: Re: Proposed Agenda - Dec 8 CDC/Merck Meeting

Sure, I will send you an updated org chart tomorrow.

We do have a scheduling problem now as I just learned Anne is going to be out of the country December 8th. I am checking on other dates/times and will get back with you as soon as possible.

Kristin Pope
NCIRD, CDC

Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 05:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

One more thing. I realize that some of the CDC folks who will be on this call on Dec 8 are in new positions. Is there an updated set of org charts showing who now does what, please? I did not see an update on the CDC website.

Thanks.

Barb

From: Kuter, Barbara J.
Sent: Wednesday, November 19, 2014 9:26 AM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Subject: Proposed Agenda - Dec 8 CDC/Merck Meeting

Hi Kristin,

Here is a draft agenda that we can discuss on our call this morning.

I will talk with you in 5 minutes!

Barb

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information

for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Feinberg, Mark
Sent: 15 Oct 2014 14:36:07 -0400
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F
Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [mailto:acs1@cdc.gov]
Sent: Tuesday, October 14, 2014 6:25 PM
To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention

Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]

Sent: Tuesday, October 14, 2014 6:12 PM

To: Schuchat, Anne MD (CDC/OID/NCIRD)

Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding "warehousing" of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark

Sent: Thursday, September 18, 2014 3:44 PM

To: Schuchat, Anne MD (CDC/OID/NCIRD)

Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components

of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark; WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fpx9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes

President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.s.html>. It may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.s.html>. It may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.s.html>. It may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Mark Feinberg
Sent: 22 Oct 2014 20:41:30 -0400
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Judy Carroll; Arlene F Brown
Subject: Greetings and follow up

Dear Kristin,

I hope you are doing well.

I have been looking forward to connecting with you to follow up on my recent exchanges with Anne about scheduling a dialog with the CDC team about the transition from 4-valent to 9-valent HPV vaccine.

Unfortunately, I have to ask you to reschedule our planned call. Like Anne and Melinda, I have had my plans evolve to be able to attend the Ebola vaccine meeting at the WHO. As such, I will be in Geneva at the time we had arranged to talk. I will be back in the US this weekend.

Would it be simplest and perhaps most productive if we can meet sometime around the ACIP meeting next week? I am sure your schedule may be busy around the meeting, but I will do my best to adjust my schedule to match your availability. If this doesn't work, let me know if there is another time on Monday or Tuesday that would work for you.

I apologize for any inconvenience, and do look forward to talking with you.

Thanks very much.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

From: Feinberg, Mark
Sent: 30 Oct 2014 17:38:37 +0000
To: Feinberg, Mark;Pope, Kristin (CDC/OID/NCIRD);Keane, Maggie;McCafferty, Julie Parkinson;Kuter, Barbara J.
Subject: HPV Vaccine Transition (M. Feinberg/K. Pope/M. Keane/J. McCafferty/B. Kuter)

***** DO NOT DELETE OR CHANGE ANY OF THE TEXT BELOW THIS LINE *****

JOIN USING WebEx

Go To:
<https://merck.webex.com/merck/j.php?J=746406876>

Meeting Password ----- This meeting does not require a password.
Meeting Number ----- 746 406 876

AUDIO CONNECTION

Provide your phone number when you join the meeting to receive a call back. Alternatively, you can call:

Call-in toll-free number: 1-866-2461076 (US)

Call-in number: 1-224-3572872 (US)

Show global numbers: <https://www.tcconline.com/offSite/OffSiteController.jsp?cc=6153777461>

Conference Code (b)(6)

IMPORTANT NOTICE: This WebEx service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation.

<http://www.webex.com>

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 10 Nov 2014 22:10:42 +0000
To: Kuter, Barbara J. (barbara_kuter@merck.com)
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: Meeting with NCIRD

Hi Barb,

It was good talking with you and your group last week about scheduling a meeting with Merck and NCIRD leadership to discuss the HPV9 transition. I have a few dates to offer below, and as we discussed last week, we can schedule additional meetings with program staff and others as your schedule allows. I am sure you understand that Anne's schedule is a bit in flux. These dates look good for her now, but things are a bit dynamic and could change. But we have to start somewhere, so please let me know if either of these work for you. Yours, Kristin

Monday, Nov. 24th 3-4pm

Monday Dec. 8th 3-4pm

Kristin Pope, M.Ed.

Associate Director for Policy

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

Kfp7@cdc.gov

Office: 404-639-8714

Cell: 404-433-6121

Teleworking Tuesdays and Thursdays

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 4 Dec 2014 14:00:02 +0000
To: 'Kuter, Barbara J.'
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Hi Barb,

I had a chance to discuss with a few of the folks that will be attending the call on December 15th, and in addition to the HPV9 timeline and coordination of messaging, it was also suggested that we add to the topics what your plans are for media campaign , and timeline for a 2-dose schedule.

Hope you had a nice Thanksgiving! Yours, Kristin

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Monday, November 24, 2014 11:25 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting dial information

Hi Kristin,

Thanks for the update & the call in number. We will get some background information to you a few days in advance of the meeting.

And just a few more questions, please:

1. Can you confirm who will be attending the meeting from your end?
2. Do you want me to continue to communicate with you as the point of contact or with Candice?
I can certainly copy both of you if that works best.
3. Are there any specific questions from the CDC staff that we should address other than what we have on the agenda thus far? Perhaps more questions will arise after we send the background slides – we can certainly check in at that point as well.

Thanks again and have a wonderful Thanksgiving !

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Monday, November 24, 2014 11:14 AM
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: Dec. 15th CDC/Merck meeting dial information

Hi Barb,

I hope you had a nice weekend.

We will be using this bridge line for the call on December 15th: 866-736-9302; passcode (b)(6)

I think the agenda items you shared are good - particularly the rollout plans/timeline and coordination of messaging around potential delays and use (revaccination, interchangeability, etc). Given there is only an hour, I think leaving time for discussion will be helpful and if there are any pre-read materials you want to share we can make sure everyone has them in advance.

Hopefully there won't be any more changes with Anne's schedule! I will be out of the country on the 15th so I won't be joining the call but Candice Swartwood (copied here) will be acting Policy Director while I am away.

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 3:11 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Let's go with 4-5 on Dec 15.

Please let me know if you would like any changes made to the agenda or if there are any specific questions you would like us to address.

Have a good weekend!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Friday, November 21, 2014 12:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

I think Anne should be back in the office on 12/15, so either time should work.

This is the earliest date she has available, and hopefully there won't be any further glitches!

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 12:20 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

Thanks for the org chart – very helpful.

I am sure we can figure out how to make Dec 15 work. Please give me a day or so to see which time is better at this end. Do you think 4-5 might be better for Anne?

And I will ask the obvious – I assume there is no way we can talk during the first week of December, correct?

Thanks again!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Thursday, November 20, 2014 1:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Attached is the most recent NCIRD org chart. Let me know if you have any questions.

I know this option isn't ideal, but would either of these work for your group?

Monday, December 15th – 11am- 12pm or 4-5pm

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 8:29 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Thanks for the heads up re the date.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, November 19, 2014 7:05 PM
To: Kuter, Barbara J.
Subject: Re: Proposed Agenda - Dec 8 CDC/Merck Meeting

Sure, I will send you an updated org chart tomorrow.

We do have a scheduling problem now as I just learned Anne is going to be out of the country December 8th. I am checking on other dates/times and will get back with you as soon as possible.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 05:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

One more thing. I realize that some of the CDC folks who will be on this call on Dec 8 are in new positions. Is there an updated set of org charts showing who now does what, please? I did not see an update on the CDC website.

Thanks.

Barb

From: Kuter, Barbara J.
Sent: Wednesday, November 19, 2014 9:26 AM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Subject: Proposed Agenda - Dec 8 CDC/Merck Meeting

Hi Kristin,

Here is a draft agenda that we can discuss on our call this morning.

I will talk with you in 5 minutes!

Barb

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station,

New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 4 Dec 2014 14:26:14 +0000
To: 'Kuter, Barbara J.'
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Yes it is! I think the background slides will be really helpful. And getting on Anne's calendar is really hard, but after this call occurs we can certainly schedule follow ups with program/comms staff as needed for further discussion.

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Thursday, December 04, 2014 9:23 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

OK – this will be a lot to cover in one hour! We will add some info to the background slides to address these points and can discuss as appropriate.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Thursday, December 04, 2014 9:00 AM
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Hi Barb,

I had a chance to discuss with a few of the folks that will be attending the call on December 15th, and in addition to the HPV9 timeline and coordination of messaging, it was also suggested that we add to the topics what your plans are for media campaign , and timeline for a 2-dose schedule.

Hope you had a nice Thanksgiving! Yours, Kristin

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Monday, November 24, 2014 11:25 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting dial information

Hi Kristin,

Thanks for the update & the call in number. We will get some background information to you a few days in advance of the meeting.

And just a few more questions, please:

1. Can you confirm who will be attending the meeting from your end?

2. Do you want me to continue to communicate with you as the point of contact or with Candice? I can certainly copy both of you if that works best.
3. Are there any specific questions from the CDC staff that we should address other than what we have on the agenda thus far? Perhaps more questions will arise after we send the background slides – we can certainly check in at that point as well.

Thanks again and have a wonderful Thanksgiving !

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Monday, November 24, 2014 11:14 AM
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: Dec. 15th CDC/Merck meeting dial information

Hi Barb,

I hope you had a nice weekend.

We will be using this bridge line for the call on December 15th: 866-736-9302; passcode

(b)(6)

I think the agenda items you shared are good - particularly the rollout plans/timeline and coordination of messaging around potential delays and use (revaccination, interchangeability, etc). Given there is only an hour, I think leaving time for discussion will be helpful and if there are any pre-read materials you want to share we can make sure everyone has them in advance.

Hopefully there won't be any more changes with Anne's schedule! I will be out of the country on the 15th so I won't be joining the call but Candice Swartwood (copied here) will be acting Policy Director while I am away.

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 3:11 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Let's go with 4-5 on Dec 15.

Please let me know if you would like any changes made to the agenda or if there are any specific questions you would like us to address.

Have a good weekend!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Friday, November 21, 2014 12:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

I think Anne should be back in the office on 12/15, so either time should work.

This is the earliest date she has available, and hopefully there won't be any further glitches!

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 12:20 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

Thanks for the org chart – very helpful.

I am sure we can figure out how to make Dec 15 work. Please give me a day or so to see which time is better at this end. Do you think 4-5 might be better for Anne?

And I will ask the obvious – I assume there is no way we can talk during the first week of December, correct?

Thanks again!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Thursday, November 20, 2014 1:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Attached is the most recent NCIRD org chart. Let me know if you have any questions.

I know this option isn't ideal, but would either of these work for your group?

Monday, December 15th – 11am- 12pm or 4-5pm

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 8:29 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Thanks for the heads up re the date.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, November 19, 2014 7:05 PM
To: Kuter, Barbara J.
Subject: Re: Proposed Agenda - Dec 8 CDC/Merck Meeting

Sure, I will send you an updated org chart tomorrow.

We do have a scheduling problem now as I just learned Anne is going to be out of the country December 8th. I am checking on other dates/times and will get back with you as soon as possible.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 05:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

One more thing. I realize that some of the CDC folks who will be on this call on Dec 8 are in new positions. Is there an updated set of org charts showing who now does what, please? I did not see an update on the CDC website.

Thanks.

Barb

From: Kuter, Barbara J.
Sent: Wednesday, November 19, 2014 9:26 AM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Subject: Proposed Agenda - Dec 8 CDC/Merck Meeting

Hi Kristin,

Here is a draft agenda that we can discuss on our call this morning.

I will talk with you in 5 minutes!

Barb

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are

not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 4 Dec 2014 16:24:49 +0000
To: 'Kuter, Barbara J.'
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Yes, we've gotten updates at our cross-agency meetings about those discussions, so hopefully this call will be an opportunity to have dialogue with Anne around some of the bigger picture issues. Thanks again for your flexibility with the scheduling!

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Thursday, December 04, 2014 9:44 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Kristin,

Sounds good. Just so you know, we have been having frequent meetings with the Communications folks and scientific staff at CDC around HPV for the past few years. So any follow-up from this meeting will likely end up being discussed in that forum.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kf.p7@cdc.gov>]
Sent: Thursday, December 04, 2014 9:26 AM
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Yes it is! I think the background slides will be really helpful. And getting on Anne's calendar is really hard, but after this call occurs we can certainly schedule follow ups with program/comms staff as needed for further discussion.

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Thursday, December 04, 2014 9:23 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

OK – this will be a lot to cover in one hour! We will add some info to the background slides to address these points and can discuss as appropriate.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kf.p7@cdc.gov>]
Sent: Thursday, December 04, 2014 9:00 AM
To: Kuter, Barbara J.

Cc: Swartwood, Cardice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Hi Barb,

I had a chance to discuss with a few of the folks that will be attending the call on December 15th, and in addition to the HPV9 timeline and coordination of messaging, it was also suggested that we add to the topics what your plans are for media campaign , and timeline for a 2-dose schedule.

Hope you had a nice Thanksgiving! Yours, Kristin

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Monday, November 24, 2014 11:25 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Cardice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting dial information

Hi Kristin,

Thanks for the update & the call in number. We will get some background information to you a few days in advance of the meeting.

And just a few more questions, please:

1. Can you confirm who will be attending the meeting from your end?
2. Do you want me to continue to communicate with you as the point of contact or with Candice?
I can certainly copy both of you if that works best.
3. Are there any specific questions from the CDC staff that we should address other than what we have on the agenda thus far? Perhaps more questions will arise after we send the background slides – we can certainly check in at that point as well.

Thanks again and have a wonderful Thanksgiving !

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [mailto:kf_p7@cdc.gov]
Sent: Monday, November 24, 2014 11:14 AM
To: Kuter, Barbara J.
Cc: Swartwood, Cardice (CDC/OID/NCIRD)
Subject: Dec. 15th CDC/Merck meetingdial information

Hi Barb,

I hope you had a nice weekend.

We will be using this bridge line for the call on December 15th: 866-736-9302; passcode (b)(6)

I think the agenda items you shared are good - particularly the rollout plans/timeline and coordination of messaging around potential delays and use (revaccination, interchangeability, etc). Given there is only an hour, I think leaving time for discussion will be helpful and if there are any pre-read materials you want to share we can make sure everyone has them in advance.

Hopefully there won't be any more changes with Anne's schedule! I will be out of the country on the 15th so I won't be joining the call but Candice Swartwood (copied here) will be acting Policy Director while I am away.

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 3:11 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Let's go with 4-5 on Dec 15.

Please let me know if you would like any changes made to the agenda or if there are any specific questions you would like us to address.

Have a good weekend!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Friday, November 21, 2014 12:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

I think Anne should be back in the office on 12/15, so either time should work.

This is the earliest date she has available, and hopefully there won't be any further glitches!

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 12:20 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

Thanks for the org chart – very helpful.

I am sure we can figure out how to make Dec 15 work. Please give me a day or so to see which time is better at this end. Do you think 4-5 might be better for Anne?

And I will ask the obvious – I assume there is no way we can talk during the first week of December, correct?

Thanks again!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kf.p7@cdc.gov>]
Sent: Thursday, November 20, 2014 1:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Attached is the most recent NCIRD org chart. Let me know if you have any questions.

I know this option isn't ideal, but would either of these work for your group?

Monday, December 15th – 11am- 12pm or 4-5pm

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 8:29 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Thanks for the heads up re the date.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kf.p7@cdc.gov>]
Sent: Wednesday, November 19, 2014 7:05 PM
To: Kuter, Barbara J.
Subject: Re: Proposed Agenda - Dec 8 CDC/Merck Meeting

Sure, I will send you an updated org chart tomorrow.

We do have a scheduling problem now as I just learned Anne is going to be out of the country December 8th. I am checking on other dates/times and will get back with you as soon as possible.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 05:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

One more thing. I realize that some of the CDC folks who will be on this call on Dec 8 are in new positions. Is there an updated set of org charts showing who now does what, please? I did not see an update on the CDC website.

Thanks.

Barb

From: Kuter, Barbara J.
Sent: Wednesday, November 19, 2014 9:26 AM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Subject: Proposed Agenda - Dec 8 CDC/Merck Meeting

Hi Kristin,

Here is a draft agenda that we can discuss on our call this morning.

I will talk with you in 5 minutes!

Barb

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential,

proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error,

please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 4 Dec 2014 18:59:44 +0000
To: 'barbara_kuter@merck.com'
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: Re: Dec. 15th CDC/Merck meeting - agenda items

Yes - anything you can share about new plans to promote HPV vaccine, particularly the 9-valent.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Thursday, December 04, 2014 01:37 P M
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Hi Kristin,
One more question, please. When you mention media campaign, are you referring to the announcements we will make at launch, advertisements, and possible DTC, etc? Just want to make sure what information is needed here.

Thanks again.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [[mail to:kfp7@cdc.gov](mailto:kfp7@cdc.gov)]
Sent: Thursday, December 04, 2014 11:25 AM
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Yes, we've gotten updates at our cross-agency meetings about those discussions, so hopefully this call will be an opportunity to have dialogue with Anne around some of the bigger picture issues. Thanks again for your flexibility with the scheduling!

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Thursday, December 04, 2014 9:44 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Kristin,

Sounds good. Just so you know, we have been having frequent meetings with the Communications folks and scientific staff at CDC around HPV for the past few years. So any follow-up from this meeting will likely end up being discussed in that forum.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [\[mailto:kfp7@cdc.gov\]](mailto:kfp7@cdc.gov)
Sent: Thursday, December 04, 2014 9:26 AM
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Yes it is! I think the background slides will be really helpful. And getting on Anne's calendar is really hard, but after this call occurs we can certainly schedule follow ups with program/comms staff as needed for further discussion.

From: Kuter, Barbara J. [\[mailto:barbara_kuter@merck.com\]](mailto:barbara_kuter@merck.com)
Sent: Thursday, December 04, 2014 9:23 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

OK – this will be a lot to cover in one hour! We will add some info to the background slides to address these points and can discuss as appropriate.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [\[mailto:kfp7@cdc.gov\]](mailto:kfp7@cdc.gov)
Sent: Thursday, December 04, 2014 9:00 AM
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting - agenda items

Hi Barb,

I had a chance to discuss with a few of the folks that will be attending the call on December 15th, and in addition to the HPV9 timeline and coordination of messaging, it was also suggested that we add to the topics what your plans are for media campaign, and timeline for a 2-dose schedule.

Hope you had a nice Thanksgiving! Yours, Kristin

From: Kuter, Barbara J. [\[mailto:barbara_kuter@merck.com\]](mailto:barbara_kuter@merck.com)
Sent: Monday, November 24, 2014 11:25 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting dial information

Hi Kristin,

Thanks for the update & the call in number. We will get some background information to you a few days in advance of the meeting.

And just a few more questions, please:

1. Can you confirm who will be attending the meeting from your end?
2. Do you want me to continue to communicate with you as the point of contact or with Candice? I can certainly copy both of you if that works best.
3. Are there any specific questions from the CDC staff that we should address other than what we have on the agenda thus far? Perhaps more questions will arise after we send the background slides – we can certainly check in at that point as well.

Thanks again and have a wonderful Thanksgiving !

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [\[mailto:kfp7@cdc.gov\]](mailto:kfp7@cdc.gov)
Sent: Monday, November 24, 2014 11:14 AM
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: Dec. 15th CDC/Merck meeting dial information

Hi Barb,

I hope you had a nice weekend.

We will be using this bridge line for the call on December 15th: 866-736-9302; passcode (b)(6)

I think the agenda items you shared are good - particularly the rollout plans/timeline and coordination of messaging around potential delays and use (revaccination, interchangeability, etc). Given there is only an hour, I think leaving time for discussion will be helpful and if there are any pre-read materials you want to share we can make sure everyone has them in advance.

Hopefully there won't be any more changes with Anne's schedule! I will be out of the country on the 15th so I won't be joining the call but Candice Swartwood (copied here) will be acting Policy Director while I am away.

From: Kuter, Barbara J. [\[mailto:barbara_kuter@merck.com\]](mailto:barbara_kuter@merck.com)
Sent: Friday, November 21, 2014 3:11 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Let's go with 4-5 on Dec 15.

Please let me know if you would like any changes made to the agenda or if there are any specific questions you would like us to address.

Have a good weekend!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [\[mailto:kfp7@cdc.gov\]](mailto:kfp7@cdc.gov)
Sent: Friday, November 21, 2014 12:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

I think Anne should be back in the office on 12/15, so either time should work.

This is the earliest date she has available, and hopefully there won't be any further glitches!

From: Kuter, Barbara J. [\[mailto:barbara_kuter@merck.com\]](mailto:barbara_kuter@merck.com)
Sent: Friday, November 21, 2014 12:20 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

Thanks for the org chart – very helpful.

I am sure we can figure out how to make Dec 15 work. Please give me a day or so to see which time is better at this end. Do you think 4-5 might be better for Anne?

And I will ask the obvious – I assume there is no way we can talk during the first week of December, correct?

Thanks again!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [\[mailto:kfp7@cdc.gov\]](mailto:kfp7@cdc.gov)
Sent: Thursday, November 20, 2014 1:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Attached is the most recent NCIRD org chart. Let me know if you have any questions.

I know this option isn't ideal, but would either of these work for your group?

Monday, December 15th – 11am- 12pm or 4-5pm

From: Kuter, Barbara J. [\[mailto:barbara_kuter@merck.com\]](mailto:barbara_kuter@merck.com)
Sent: Wednesday, November 19, 2014 8:29 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Thanks for the heads up re the date.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [\[mailto:kfp7@cdc.gov\]](mailto:kfp7@cdc.gov)
Sent: Wednesday, November 19, 2014 7:05 PM
To: Kuter, Barbara J.
Subject: Re: Proposed Agenda - Dec 8 CDC/Merck Meeting

Sure, I will send you an updated org chart tomorrow.

We do have a scheduling problem now as I just learned Anne is going to be out of the country December 8th. I am checking on other dates/times and will get back with you as soon as possible.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [\[mailto:barbara_kuter@merck.com\]](mailto:barbara_kuter@merck.com)
Sent: Wednesday, November 19, 2014 05:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

One more thing. I realize that some of the CDC folks who will be on this call on Dec 8 are in new positions. Is there an updated set of org charts showing who now does what, please? I did not see an update on the CDC website.

Thanks.

Barb

From: Kuter, Barbara J.
Sent: Wednesday, November 19, 2014 9:26 AM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Subject: Proposed Agenda - Dec 8 CDC/Merck Meeting

Hi Kristin,

Here is a draft agenda that we can discuss on our call this morning.

I will talk with you in 5 minutes!

Barb

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station,

New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential,

proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 24 Nov 2014 16:35:53 +0000
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting dial information

At this point, the NCIRD attendees are:

- Anne Schuchat, NCIRD Director
- Nancy Messonnier, NCIRD Deputy
- Melinda Wharton, ISD Director
- Amanda Cohn, ISD Deputy
- Kris Sheedy, NCIRD Director for Health Communications
- Michelle Basket, NCIRD Deputy for Health Communications
- Candice Swartwood, NCIRD Deputy for Policy

As we discussed last week, Anne preferred a smaller meeting to discuss some of the bigger-picture issues, but Melinda is out of the office this week and I don't know if she will invite others from her Division to participate, such as Shannon Stokley and Brooke Barry.

If you don't mind copying both Candice and me that would be great.

And I think for this meeting the key questions are probably around the rollout and Merck's plans to transition to the new product and efforts to minimize confusion/delay/disruption. But I agree that following the review of background information more specific questions may arise, so we can circle back close to the call.

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Monday, November 24, 2014 11:25 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: RE: Dec. 15th CDC/Merck meeting dial information

Hi Kristin,

Thanks for the update & the call in number. We will get some background information to you a few days in advance of the meeting.

And just a few more questions, please:

1. Can you confirm who will be attending the meeting from your end?
2. Do you want me to continue to communicate with you as the point of contact or with Candice? I can certainly copy both of you if that works best.
3. Are there any specific questions from the CDC staff that we should address other than what we have on the agenda thus far? Perhaps more questions will arise after we send the background slides – we can certainly check in at that point as well.

Thanks again and have a wonderful Thanksgiving !

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Monday, November 24, 2014 11:14 AM
To: Kuter, Barbara J.
Cc: Swartwood, Candice (CDC/OID/NCIRD)
Subject: Dec. 15th CDC/Merck meeting dial information

Hi Barb,

I hope you had a nice weekend.

We will be using this bridge line for the call on December 15th: 866-736-9302; passcode (b)(6)

I think the agenda items you shared are good - particularly the rollout plans/timeline and coordination of messaging around potential delays and use (revaccination, interchangeability, etc). Given there is only an hour, I think leaving time for discussion will be helpful and if there are any pre-read materials you want to share we can make sure everyone has them in advance.

Hopefully there won't be any more changes with Anne's schedule! I will be out of the country on the 15th so I won't be joining the call but Candice Swartwood (copied here) will be acting Policy Director while I am away.

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 3:11 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Let's go with 4-5 on Dec 15.

Please let me know if you would like any changes made to the agenda or if there are any specific questions you would like us to address.

Have a good weekend!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Friday, November 21, 2014 12:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

I think Anne should be back in the office on 12/15, so either time should work.

This is the earliest date she has available, and hopefully there won't be any further glitches!

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 12:20 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

Thanks for the org chart – very helpful.

I am sure we can figure out how to make Dec 15 work. Please give me a day or so to see which time is better at this end. Do you think 4-5 might be better for Anne?

And I will ask the obvious – I assume there is no way we can talk during the first week of December, correct?

Thanks again!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Thursday, November 20, 2014 1:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Attached is the most recent NCIRD org chart. Let me know if you have any questions.

I know this option isn't ideal, but would either of these work for your group?

Monday, December 15th – 11am- 12pm or 4-5pm

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 8:29 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Thanks for the heads up re the date.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, November 19, 2014 7:05 PM
To: Kuter, Barbara J.
Subject: Re: Proposed Agenda - Dec 8 CDC/Merck Meeting

Sure, I will send you an updated org chart tomorrow.

We do have a scheduling problem now as I just learned Anne is going to be out of the country December

8th. I am checking on other dates/times and will get back with you as soon as possible.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 05:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

One more thing. I realize that some of the CDC folks who will be on this call on Dec 8 are in new positions. Is there an updated set of org charts showing who now does what, please? I did not see an update on the CDC website.

Thanks.

Barb

From: Kuter, Barbara J.
Sent: Wednesday, November 19, 2014 9:26 AM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Subject: Proposed Agenda - Dec 8 CDC/Merck Meeting

Hi Kristin,

Here is a draft agenda that we can discuss on our call this morning.

I will talk with you in 5 minutes!

Barb

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Schuchat, Anne MD (CDC/OID/NCIRD)
Sent: 14 Oct 2014 18:24:33 -0400
To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark; WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fpx9@cdc.gov; duk3@cdc.gov

Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.shtml>. It may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information

for affiliates is available at

<http://www.merck.com/contact/contacts.htm> It may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 15 Oct 2014 20:38:05 +0000
To: Feinberg, Mark
Cc: Brown, Arlene F
Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Wednesday, October 15, 2014 2:36 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F
Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [mailto:acs1@cdc.gov]
Sent: Tuesday, October 14, 2014 6:25 PM
To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the Hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD);

Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark; WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fpx9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.shtml>. It may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.shtml>. It may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.shtml>. It may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely

for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Feinberg, Mark
Sent: 28 Oct 2014 16:46:05 -0400
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: Re: Greetings and Follow Up

Thanks very much. We look forward to seeing you there and then.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Oct 28, 2014, at 4:30 PM, Pope, Kristin (CDC/OID/NCIRD) <kfp7@cdc.gov> wrote:

Sure – let's meet outside the auditorium and if quiet enough we can grab a table there or we can head to the cafeteria. my cell is 404-433-6121.

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 28, 2014 4:23 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Sounds great. Thanks very much (although I have a feeling that I still owe Barb an almond croissant from Alon's).

Should we meet you outside the auditorium where the ACIP meeting will be taking place? If you need to reach me, my cell phone is (b)(6) Please let me know how I can contact you (in case of last minute changes in plans).

We look forward to seeing you.

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Tuesday, October 28, 2014 4:19 PM
To: Feinberg, Mark
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Hi Mark,

10am on Thursday would be better for me if that works for all of you. Thanks, Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 28, 2014 4:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well.

I am writing to follow up on our earlier email exchange and to see if you might be able to get together in person this Thursday with me and my colleagues Barb Kuter and Julie McCafferty to discuss how to structure/advance the discussion with Anne, Melinda and other members of the very able CDC team about the pending transition from the 4-valent to 9-valent HPV vaccine. I am sure that your schedule has been as or more complicated as mine of recent, given all the significant and diverse issues the CDC is currently dealing with. If you do have time on Thursday, that would be great. If not, perhaps we can connect again by phone sometime soon. Of potential times on Thursday, might you either be free to get together at 7:30 AM (I would be happy to stop by Alon's and get some breakfast selections!) before the ACIP meeting or potentially at 10 AM (during the typhoid vaccine discussion)? These times would work for me, Barb and Julie.

We look forward to (hopefully) seeing you soon.

Thanks very much,

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, October 15, 2014 4:38 PM
To: Feinberg, Mark
Cc: Brown, Arlene F
Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office.
Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Wednesday, October 15, 2014 2:36 PM
To: Pope, Kristin (CDC/OID/NCIRD)

Cc: Brown, Arlene F
Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]
Sent: Tuesday, October 14, 2014 6:25 PM
To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who

have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara

Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR);
Bresnitz, Eddy A.

Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]

Sent: Tuesday, August 26, 2014 6:21 PM

To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark;
WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F

Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F;
fpx9@cdc.gov; duk3@cdc.gov

Subject: Hilleman Lecture Update

Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential,

proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 30 Oct 2014 14:00:47 +0000
To: 'mark_feinberg@merck.com'
Cc: 'arlene_brown@merck.com'; 'barbara_kuter@merck.com'; 'julie_mccafferty@merck.com'; 'maggie_keane@merck.com'
Subject: Re: Greetings and Follow Up

Hi Mark,

I have to cover a meeting for Anne at 10:15. Not sure how long the call will go, and happy to try to meet after if possible although hpv is up at 11!

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 28, 2014 04:46 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F <arlene_brown@merck.com>; Kuter, Barbara J. <barbara_kuter@merck.com>; McCafferty, Julie Parkinson <julie_mccafferty@merck.com>; Keane, Maggie <maggie_keane@merck.com>
Subject: Re: Greetings and Follow Up

Thanks very much. We look forward to seeing you there and then.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Oct 28, 2014, at 4:30 PM, Pope, Kristin (CDC/OID/NCIRD) <kfp7@cdc.gov> wrote:

Sure – let's meet outside the auditorium and if quiet enough we can grab a table there or we can head to the cafeteria. my cell is 404-433-6121.

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent : Tuesday, October 28, 2014 4:23 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Sounds great. Thanks very much (although I have a feeling that I still owe Barb an almond croissant from Alon's).

Should we meet you outside the auditorium where the ACIP meeting will be taking place? If you need to reach me, my cell phone is (b)(6) Please let me know how I can contact you (in case of last minute changes in plans).

We look forward to seeing you.

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent : Tuesday, October 28, 2014 4:19 PM
To: Feinberg, Mark
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Hi Mark,

10am on Thursday would be better for me if that works for all of you. Thanks, Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent : Tuesday, October 28, 2014 4:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well.

I am writing to follow up on our earlier email exchange and to see if you might be able to get together in person this Thursday with me and my colleagues Barb Kuter and Julie McCafferty to discuss how to structure/advance the discussion with Anne, Melinda and other members of the very able CDC team about the pending transition from the 4-valent to 9-valent HPV vaccine. I am sure that your schedule has been as or more complicated as mine of recent, given all the significant and diverse issues the CDC is currently dealing with. If you do have time on Thursday, that would be great. If not, perhaps we can connect again by phone sometime soon. Of potential times on Thursday, might you either be free to get together at 7:30 AM (I would be happy to stop by Alon's and get some breakfast selections!) before the ACIP meeting or potentially at 10 AM (during the typhoid vaccine discussion)? These times would work for me, Barb and Julie.

We look forward to (hopefully) seeing you soon.

Thanks very much,

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent : Wednesday, October 15, 2014 4:38 PM
To: Feinberg, Mark
Cc: Brown, Arlene F
Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office.
Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent : Wednesday, October 15, 2014 2:36 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F
Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]
Sent : Tuesday, October 14, 2014 6:25 PM
To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]

Sent : Tuesday, October 14, 2014 6:12 PM

To: Schuchat, Anne MD (CDC/OID/NCIRD)

Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent : Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM

To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark;
WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene
F; fpx9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are

not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station,

New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Feinberg, Mark
Sent: 30 Oct 2014 10:07:24 -0400
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F;Kuter, Barbara J.;McCafferty, Julie Parkinson;Keane, Maggie
Subject: Re: Greetings and Follow Up

Hi Kristin,

Thanks for the update. Rather than rush your meeting with Anne or impinge on us all participating in the HPV vaccine session, we can hopefully find a time to connect by phone sometime soon. Let me know some potential times that could work for you.

I hope you are doing well and look forward to talking with you.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Oct 30, 2014, at 10:01 AM, Pope, Kristin (CDC/OID/NCIRD) <kfp7@cdc.gov> wrote:

Hi Mark,

I have to cover a meeting for Anne at 10:15. Not sure how long the call will go, and happy to try to meet after if possible although hpv is up at 11!

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent : Tuesday, October 28, 2014 04:46 PM
To : Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F <arlene_brown@merck.com>; Kuter, Barbara J. <barbara_kuter@merck.com>; McCafferty, Julie Parkinson <julie_mccafferty@merck.com>; Keane, Maggie <maggie_keane@merck.com>
Subject: Re: Greetings and Follow Up

Thanks very much. We look forward to seeing you there and then.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Oct 28, 2014, at 4:30 PM, Pope, Kristin (CDC/OID/NCIRD) <kfp7@cdc.gov> wrote:

Sure – let's meet outside the auditorium and if quiet enough we can grab a table there or we can head to the cafeteria. my cell is 404-433-6121.

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent : Tuesday, October 28, 2014 4:23 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject : RE: Greetings and Follow Up

Sounds great. Thanks very much (although I have a feeling that I still owe Barb an almond croissant from Alon's).

Should we meet you outside the auditorium where the ACIP meeting will be taking place? If you need to reach me, my cell phone is (b)(6) Please let me know how I can contact you (in case of last minute changes in plans).

We look forward to seeing you.

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent : Tuesday, October 28, 2014 4:19 PM
To: Feinberg, Mark
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject : RE: Greetings and Follow Up

Hi Mark,

10am on Thursday would be better for me if that works for all of you.
Thanks, Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent : Tuesday, October 28, 2014 4:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane,

Maggie

Subject: RE: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well.

I am writing to follow up on our earlier email exchange and to see if you might be able to get together in person this Thursday with me and my colleagues Barb Kuter and Julie McCafferty to discuss how to structure/advance the discussion with Anne, Melinda and other members of the very able CDC team about the pending transition from the 4-valent to 9-valent HPV vaccine. I am sure that your schedule has been as or more complicated as mine of recent, given all the significant and diverse issues the CDC is currently dealing with. If you do have time on Thursday, that would be great. If not, perhaps we can connect again by phone sometime soon. Of potential times on Thursday, might you either be free to get together at 7:30 AM (I would be happy to stop by Alon's and get some breakfast selections!) before the ACIP meeting or potentially at 10 AM (during the typhoid vaccine discussion)? These times would work for me, Barb and Julie.

We look forward to (hopefully) seeing you soon.

Thanks very much,

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]

Sent: Wednesday, October 15, 2014 4:38 PM

To: Feinberg, Mark

Cc: Brown, Arlene F

Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]

Sent: Wednesday, October 15, 2014 2:36 PM

To: Pope, Kristin (CDC/OID/NCIRD)

Cc: Brown, Arlene F

Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]
Sent : Tuesday, October 14, 2014 6:25 PM
To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent : Tuesday, October 14, 2014 6:12 PM

To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you

would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark; WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fp9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message

in error,
please notify us immediately by reply e-mail and then
delete it from
your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 30 Oct 2014 14:11:47 +0000
To: 'Feinberg, Mark'
Cc: Brown, Arlene F.; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Thanks so much for your understanding. Next week I am free Tuesday after 1pm, Wednesday after 3pm or Thursday between 10am-2pm.

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, October 30, 2014 10:07 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F.; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: Re: Greetings and Follow Up

Hi Kristin,

Thanks for the update. Rather than rush your meeting with Anne or impinge on us all participating in the HPV vaccine session, we can hopefully find a time to connect by phone sometime soon. Let me know some potential times that could work for you.

I hope you are doing well and look forward to talking with you.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Oct 30, 2014, at 10:01 AM, Pope, Kristin (CDC/OID/NCIRD) <kfp7@cdc.gov> wrote:

Hi Mark,

I have to cover a meeting for Anne at 10:15. Not sure how long the call will go, and happy to try to meet after if possible although hpv is up at 11!

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 28, 2014 04:46 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F. <arlene_brown@merck.com>; Kuter, Barbara J. <barbara_kuter@merck.com>; McCafferty, Julie Parkinson <julie_mccafferty@merck.com>; Keane, Maggie <maggie_keane@merck.com>

Subject: Re: Greetings and Follow Up

Thanks very much. We look forward to seeing you there and then.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Oct 28, 2014, at 4:30 PM, Pope, Kristin (CDC/OID/NCIRD) <kfp7@cdc.gov> wrote:

Sure – let's meet outside the auditorium and if quiet enough we can grab a table there or we can head to the cafeteria. my cell is 404-433-6121.

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 28, 2014 4:23 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson Keane, Maggie
Subject: RE: Greetings and Follow Up

Sounds great. Thanks very much (although I have a feeling that I still owe Barb an almond croissant from Alon's).

Should we meet you outside the auditorium where the ACIP meeting will be taking place? If you need to reach me, my cell phone is (b)(6). Please let me know how I can contact you (in case of last minute changes in plans).

We look forward to seeing you.

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [mailto:kfp7@cdc.gov]
Sent: Tuesday, October 28, 2014 4:19 PM
To: Feinberg, Mark
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson Keane, Maggie
Subject: RE: Greetings and Follow Up

Hi Mark,

10am on Thursday would be better for me if that works for all of you.
Thanks, Kristin

From: Feinberg, Mark [[mail to: mark.feinberg@merck.com](mailto:mark.feinberg@merck.com)]
Sent: Tuesday, October 28, 2014 4:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson Keane, Maggie
Subject: RE: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well.

I am writing to follow up on our earlier email exchange and to see if you might be able to get together in person this Thursday with me and my colleagues Barb Kuter and Julie McCafferty to discuss how to structure/advance the discussion with Anne, Melinda and other members of the very able CDC team about the pending transition from the 4-valent to 9-valent HPV vaccine. I am sure that your schedule has been as or more complicated as mine of recent, given all the significant and diverse issues the CDC is currently dealing with. If you do have time on Thursday, that would be great. If not, perhaps we can connect again by phone sometime soon. Of potential times on Thursday, might you either be free to get together at 7:30 AM (I would be happy to stop by Alon's and get some breakfast selections!) before the ACIP meeting or potentially at 10 AM (during the typhoid vaccine discussion)? These times would work for me, Barb and Julie.

We look forward to (hopefully) seeing you soon.

Thanks very much,

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [[mail to: kfp7@cdc.gov](mailto:kfp7@cdc.gov)]
Sent: Wednesday, October 15, 2014 4:38 PM
To: Feinberg, Mark
Cc: Brown, Arlene F
Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Feinberg, Mark [[mail to: mark.feinberg@merck.com](mailto:mark.feinberg@merck.com)]
Sent: Wednesday, October 15, 2014 2:36 PM
To: Pope, Kristin (CDC/OID/NCIRD)

Cc: Brown, Arlene F

Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [mailto:acs1@cdc.gov]

Sent: Tuesday, October 14, 2014 6:25 PM

To: Feinberg, Mark

Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)

Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the Hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention

Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark.feinberg@merck.com]

Sent: Tuesday, October 14, 2014 6:12 PM

To: Schuchat, Anne MD (CDC/OID/NCIRD)

Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding "warehousing" of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark

Sent: Thursday, September 18, 2014 3:44 PM

To: Schuchat, Anne MD (CDC/OID/NCIRD)

Subject: Re: Hill Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to

you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases

Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [[mail to: mark.feinberg@merck.com](mailto:mark.feinberg@merck.com)]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC [cdcfoundation.org](mailto:cstokes@cdcfoundation.org)); Schuchat, Anne MD (CDC/OID/NCIRD); Hinnan, Alana (CDC taskforce.org); WDwdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Homan, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OO/OO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [[mail to: cstokes@cdcfoundation.org](mailto:cstokes@cdcfoundation.org)]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinnan@taskforce.org; Feinberg, Mark; WDwdle@taskforce.org; da.wn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Homan, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fp9@cdc.gov; duk3@cdc.gov

Subject: Hilleman Lecture Update

Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.shtml> that may be confidential,

proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station,

New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contacts/contactus.htm> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station,

New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contacts/contactus.htm> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station,

New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contacts/contactus.htm> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station,

New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contactus.htm>

that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contactus.htm> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contactus.htm> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Brown, Arlene F
Sent: 30 Oct 2014 13:41:58 -0400
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie; Feinberg, Mark
Subject: RE: Greetings and Follow Up

Dear Kristin,

Thank you for your quick reply. Tuesday the 4th is the best date for Mark. He leaves for India on the 5th. I have sent through an Outlook request for 3:30-4:15 pm with WebEx information.

Best, Arlene

From: Pope, Kristin (CDC/OID/NCIRD) [mailto:kfp7@cdc.gov]
Sent: Thursday, October 30, 2014 10:12 AM
To: Feinberg, Mark
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Thanks so much for your understanding. Next week I am free Tuesday after 1pm, Wednesday after 3pm or Thursday between 10am-2pm.

From: Feinberg, Mark [mailto:mark.feinberg@merck.com]
Sent: Thursday, October 30, 2014 10:07 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: Re: Greetings and Follow Up

Hi Kristin,

Thanks for the update. Rather than rush your meeting with Anne or impinge on us all participating in the HPV vaccine session, we can hopefully find a time to connect by phone sometime soon. Let me know some potential times that could work for you.

I hope you are doing well and look forward to talking with you.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark.feinberg@merck.com

On Oct 30, 2014, at 10:01 AM, Pope, Kristin (CDC/OID/NCIRD) <kfp7@cdc.gov> wrote:

Hi Mark,

I have to cover a meeting for Anne at 10:15. Not sure how long the call will go, and happy to try to meet after if possible although hpv is up at 11!

Kristin Pope

NCIRD, CDC

Office: 404-639-8714

Cell: 404-433-6121

From: Feinberg, Mark [<mailto:mark.feinberg@merck.com>]
Sent: Tuesday, October 28, 2014 04:46 PM
To: Pope Kristin (CDC/OID/NCIRD)
Cc: Brown, ArleneF <arlene.brown@merck.com>; Kuter, BarbaraJ. <barbara.kuter@merck.com>; McCafferty, JulieParkinson <julie.mccafferty@merck.com>; Kean, Maggie <maggie.kean@merck.com>
Subject: Re: Gettings and Follow Up

Thanks very much. We look forward to seeing you there and then.

Best,

Mark

Mark Feinberg, MD, PhD

215-652-8664

mark.feinberg@merck.com

On Oct 28, 2014, at 4:30 PM, Pope, Kristin (CDC/OID/NCIRD) <kfp7@cdc.gov> wrote:

Sure – let's meet outside the auditorium and if quiet enough we can grab a table there or we can head to the cafeteria. my cell is 404-433-6121.

From: Feinberg, Mark [<mailto:mark.feinberg@merck.com>]
Sent: Tuesday, October 28, 2014 4:23 PM
To: Pope Kristin (CDC/OID/NCIRD)
Cc: Brown, ArleneF; Kuter, BarbaraJ.; McCafferty, JulieParkinson; Kean, Maggie
Subject: RE: Gettings and Follow Up

Sounds great. Thanks very much (although I have a feeling that I still owe Barban almond croissant from Alon's).

Should we meet you outside the auditorium where the ACIP meeting will be taking place? If you need to reach me, my cell phone is (b)(6). Please let me know how I can contact you (in case of last minute changes in plans).

We look forward to seeing you.

Best,

Mark

From: Pope Kristin (CDC/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Tuesday, October 28, 2014 4:19 PM
To: Fenberg, Mark
Cc: Brown, ArleneF; Kuter, Barbara J.; McCafferty, Julie Parkinson; Kene
Maggi e
Subject: RE: Gettings and Follow Up

Hi Mark,

10am on Thursday would be better for me if that works for all of you.
Thanks, Kristin

From: Fenberg, Mark [mailto:mark_fenberg@meck.com]
Sent: Tuesday, October 28, 2014 4:15 PM
To: Pope Kristin (CDC/NCIRD)
Cc: Brown, ArleneF; Kuter, Barbara J.; McCafferty, Julie Parkinson; Kene
Maggi e
Subject: RE: Gettings and Follow Up

Dear Kristin,

I hope this note finds you doing very well.

I am writing to follow up on our earlier email exchange and to see if you might be able to get together in person this Thursday with me and my colleagues Barb Kuter and Julie McCafferty to discuss how to structure/advance the discussion with Anne, Melinda and other members of the very able CDC team about the pending transition from the 4-valent to 9-valent HPV vaccine. I am sure that your schedule has been as or more complicated as mine of recent, given all the significant and diverse issues the CDC is currently dealing with. If you do have time on Thursday, that would be great. If not, perhaps we can connect again by phone sometime soon. Of potential times on Thursday, might you either be free to get together at 7:30 AM (I would be happy to stop by Alon's and get some breakfast selections!) before the ACIP meeting or potentially at 10 AM (during the typhoid vaccine discussion)? These times would work for me, Barb and Julie.

We look forward to (hopefully) seeing you soon.

Thanks very much,

Best,

Mark

From: Pope Kristin (CDC/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, October 15, 2014 4:38 PM
To: Fenberg, Mark
Cc: Brown, Arlene
Subject: RE: Gettings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Fenberg, Mark [<mailto:mark.fenberg@meck.com>]
Sent: Wednesday, October 15, 2014 2:36 PM
To: Pope Kristin (CDC/NCIRD)
Cc: Brown, Arlene
Subject: FW: Gettings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mark

From: Schuchat, Anne (CDC/NCIRD) [<mailto:acs1@cdc.gov>]
Sent: Tuesday, October 14, 2014 6:25 PM
To: Fenberg, Mark
Cc: Pope Kristin (CDC/NCIRD); Mosconi, Nancy (CDC/NCIRD)
Subject: RE: Gettings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D

pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Fernberg, Mark [<mailto:mark.fernberg@merck.com>]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (DC/D/NID)
Subject:Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, AnneMD (CDC/NID)
Subject: Re: Hi I am LectureUpdate

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Fernberg, Mark [[mail to: mark.fernberg@merck.com](mailto:mark.fernberg@merck.com)]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC/cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hilleman, Alan (CDC/taskforce.org); W Dowdle, E (taskforce.org); King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene
Cc: Honaman, Darlene; Bi-Aime, Sandra (CDC/cdcfoundation.org); Roberto, Diana (CDC/cdcfoundation.org); Brown, Arlene; Williams, Tara Y. (CDC/CFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Brenitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [[mailto: cstokes@cdcfoundation.org](mailto:cstokes@cdcfoundation.org)]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acsl@cdc.gov; ahinman@askforce.org; Feinberg, Mark;
WDowdle@askforce.org; glawn.king1@cdc.hhs.gov; Brown,
Arlene
Cc: Honaman, Darlene; Bi-Aime, Sandra; Robert, Diana;
Brown, Arlene; fp9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.shtml> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.shtml> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.shtml> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse

St at io n,
Nw Jersey, USA 08889), and/o r it s affiliat es Direc t co nt act
info rmat io n
fo r affiliat es is available at
[ht t p: //www.merck.co m/co nt act /co nt act s.ht m](http://www.merck.com/cont act /cont act s.ht m)that may be co nfident ial,
pro priet ary co pyright ed and/o r legally privileged. It is int ended so lely
fo r t he use o f t he individual o r ent it y named o n t his message. If yo u are
no t t he int ended redpient , and have received t his message in erro r,
please no t ify us immediat ely by reply e-mail and t hen delet e it fro m
yo ur syst em.

N t ice: This e-mail message, t o get her wit h any at t achment s, co nt ains
info rmat io n o f Merck & Co ., Inc (One Merck Drive, Whit eho use
St at io n,

Nw Jersey, USA 08889), and/o r it s affiliat es Direc t co nt act
info rmat io n
fo r affiliat es is available at
[ht t p: //www.merck.co m/co nt act /co nt act s.ht m](http://www.merck.com/cont act /cont act s.ht m)that may be co nfident ial,
pro priet ary co pyright ed and/o r legally privileged. It is int ended so lely
fo r t he use o f t he individual o r ent it y named o n t his message. If yo u are
no t t he int ended redpient , and have received t his message in erro r,
please no t ify us immediat ely by reply e-mail and t hen delet e it fro m
yo ur syst em.

N t ice: This e-mail message, t o get her wit h any at t achment s, co nt ains
info rmat io n o f Merck & Co ., Inc (One Merck Drive, Whit eho use St at io n,
Nw Jersey, USA 08889), and/o r it s affiliat es Direc t co nt act info rmat io n
fo r affiliat es is available at
[ht t p: //www.merck.co m/co nt act /co nt act s.ht m](http://www.merck.com/cont act /cont act s.ht m)that may be co nfident ial,
pro priet ary co pyright ed and/o r legally privileged. It is int ended so lely
fo r t he use o f t he individual o r ent it y named o n t his message. If yo u are
no t t he int ended redpient , and have received t his message in erro r,
please no t ify us immediat ely by reply e-mail and t hen delet e it fro m
yo ur syst em.

N t ice: This e-mail message, t o get her wit h any at t achment s, co nt ains
info rmat io n o f Merck & Co ., Inc (One Merck Drive, Whit eho use St at io n,
Nw Jersey, USA 08889), and/o r it s affiliat es Direc t co nt act info rmat io n
fo r affiliat es is available at
[ht t p: //www.merck.co m/co nt act /co nt act s.ht m](http://www.merck.com/cont act /cont act s.ht m)that may be co nfident ial,
pro priet ary co pyright ed and/o r legally privileged. It is int ended so lely
fo r t he use o f t he individual o r ent it y named o n t his message. If yo u are
no t t he int ended redpient , and have received t his message in erro r,
please no t ify us immediat ely by reply e-mail and t hen delet e it fro m
yo ur syst em.

N t ice: This e-mail message, t o get her wit h any at t achment s, co nt ains
info rmat io n o f Merck & Co ., Inc (One Merck Drive, Whit eho use St at io n,
Nw Jersey, USA 08889), and/o r it s affiliat es Direc t co nt act info rmat io n
fo r affiliat es is available at

http://www.merck.com/contact/contact.shtml) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Feinberg, Mark
Sent: 15 Oct 2014 16:39:11 -0400
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F
Subject: Re: Greetings and Follow Up

That's great. Thanks very much.

I look forward to talking with you.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Oct 15, 2014, at 4:38 PM, Pope, Kristin (CDC/OID/NCIRD) <kfp7@cdc.gov> wrote:

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office.
Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Wednesday, October 15, 2014 2:36 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F
Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]
Sent: Tuesday, October 14, 2014 6:25 PM
To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark;
WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fpx9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 16 Oct 2014 15:49:59 +0000
To: 'Brown, Arlene F'
Subject: RE: Greetings and Follow Up

3pm on Thursday 10/23 works great for me!

From: Brown, Arlene F [mailto:arlene_brown@merck.com]
Sent: Thursday, October 16, 2014 11:49 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Hi Kristin,

Mark could be available for a call on Tuesday 21 October between 3 and 5:00 pm. Or Thursday 23 October also between 3 and 5:00 pm.

Please let me know if one of these times would work for you

Best, Arlene

Arlene Brown

Assistant to Mark Feinberg, MD, PhD

Vice President and Chief Public Health and Science Officer

Merck Vaccines

1-215-652-8898 phone

From: Pope, Kristin (CDC/OID/NCIRD) [mailto:kfp7@cdc.gov]
Sent: Wednesday, October 15, 2014 4:38 PM
To: Feinberg, Mark
C c: Brown, Arlene F
Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Wednesday, October 15, 2014 2:36 PM
To: Pope, Kristin (CDC/OID/NCIRD)
C c: Brown, Arlene F
Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]
Sent: Tuesday, October 14, 2014 6:25 PM
To: Feinberg, Mark
C c: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
C c: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy

and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark; WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
C c: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fpx9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 16 Oct 2014 15:52:12 +0000
To: 'Brown, Arlene F'
Subject: RE: Greetings and Follow Up

He can call me directly – probably best to call my cell phone 404-433-6121.

From: Brown, Arlene F [mailto:arlene_brown@merck.com]
Sent: Thursday, October 16, 2014 11:51 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Should he call you directly, or should I set up a call in number?

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Thursday, October 16, 2014 11:50 AM
To: Brown, Arlene F
Subject: RE: Greetings and Follow Up

3pm on Thursday 10/23 works great for me!

From: Brown, Arlene F [mailto:arlene_brown@merck.com]
Sent: Thursday, October 16, 2014 11:49 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Hi Kristin,

Mark could be available for a call on Tuesday 21 October between 3 and 5:00 pm. Or Thursday 23 October also between 3 and 5:00 pm.

Please let me know if one of these times would work for you

Best, Arlene

Arlene Brown

Assistant to Mark Feinberg, MD, PhD

Vice President and Chief Public Health and Science Officer

Merck Vaccines

1-215-652-8898 phone

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, October 15, 2014 4:38 PM
To: Feinberg, Mark
C c: Brown, Arlene F
Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]

Sent: Wednesday, October 15, 2014 2:36 PM

To: Pope, Kristin (CDC/OID/NCIRD)

C c: Brown, Arlene F

Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]

Sent: Tuesday, October 14, 2014 6:25 PM

To: Feinberg, Mark

C c: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)

Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General

Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
C c: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR);

King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark; WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
C c: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fpx9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this

important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.s.htm> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.s.htm> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contact.s.htm> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error,

please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contactus.htm> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contactus.htm> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 23 Oct 2014 12:35:57 +0000
To: 'Mark Feinberg'
Cc: Judy Carroll; Arlene F Brown
Subject: RE: Greetings and follow up

Hi Mark,

I totally understand evolving plans! So no problem and I would be happy to meet at ACIP. We could either meet during a break/lunch or before/after. We can play it by ear and see how things go, but it should be no problem. I hope the meeting goes well. Safe travels, Kristin

-----Original Message-----

From: Mark Feinberg [mailto:(b)(6)]
Sent: Wednesday, October 22, 2014 8:42 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Judy Carroll; Arlene F Brown
Subject: Greetings and follow up

Dear Kristin,

I hope you are doing well.

I have been looking forward to connecting with you to follow up on my recent exchanges with Anne about scheduling a dialog with the CDC team about the transition from 4-valent to 9-valent HPV vaccine.

Unfortunately, I have to ask you to reschedule our planned call. Like Anne and Melinda, I have had my plans evolve to be able to attend the Ebola vaccine meeting at the WHO. As such, I will be in Geneva at the time we had arranged to talk. I will be back in the US this weekend.

Would it be simplest and perhaps most productive if we can meet sometime around the ACIP meeting next week? I am sure your schedule may be busy around the meeting, but I will do my best to adjust my schedule to match your availability. If this doesn't work, let me know if there is another time on Monday or Tuesday that would work for you.

I apologize for any inconvenience, and do look forward to talking with you.

Thanks very much.

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

From: Feinberg, Mark
Sent: 28 Oct 2014 16:14:55 -0400
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F;Kuter, Barbara J.;McCafferty, Julie Parkinson;Keane, Maggie
Subject: RE: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well.

I am writing to follow up on our earlier email exchange and to see if you might be able to get together in person this Thursday with me and my colleagues Barb Kuter and Julie McCafferty to discuss how to structure/advance the discussion with Anne, Melinda and other members of the very able CDC team about the pending transition from the 4-valent to 9-valent HPV vaccine. I am sure that your schedule has been as or more complicated as mine of recent, given all the significant and diverse issues the CDC is currently dealing with. If you do have time on Thursday, that would be great. If not, perhaps we can connect again by phone sometime soon. Of potential times on Thursday, might you either be free to get together at 7:30 AM (I would be happy to stop by Alon's and get some breakfast selections!) before the ACIP meeting or potentially at 10 AM (during the typhoid vaccine discussion)? These times would work for me, Barb and Julie.

We look forward to (hopefully) seeing you soon.

Thanks very much,

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [mailto:kfp7@cdc.gov]
Sent: Wednesday, October 15, 2014 4:38 PM
To: Feinberg, Mark
Cc: Brown, Arlene F
Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Wednesday, October 15, 2014 2:36 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F
Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]
Sent: Tuesday, October 14, 2014 6:25 PM
To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy

and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark; WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fpx9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml>) that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml>) that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml>) that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml>) that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 28 Oct 2014 20:18:39 +0000
To: 'Feinberg, Mark'
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Hi Mark,

10am on Thursday would be better for me if that works for all of you. Thanks, Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 28, 2014 4:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well.

I am writing to follow up on our earlier email exchange and to see if you might be able to get together in person this Thursday with me and my colleagues Barb Kuter and Julie McCafferty to discuss how to structure/advance the discussion with Anne, Melinda and other members of the very able CDC team about the pending transition from the 4-valent to 9-valent HPV vaccine. I am sure that your schedule has been as or more complicated as mine of recent, given all the significant and diverse issues the CDC is currently dealing with. If you do have time on Thursday, that would be great. If not, perhaps we can connect again by phone sometime soon. Of potential times on Thursday, might you either be free to get together at 7:30 AM (I would be happy to stop by Alon's and get some breakfast selections!) before the ACIP meeting or potentially at 10 AM (during the typhoid vaccine discussion)? These times would work for me, Barb and Julie.

We look forward to (hopefully) seeing you soon.

Thanks very much,

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [mailto:kfp7@cdc.gov]
Sent: Wednesday, October 15, 2014 4:38 PM
To: Feinberg, Mark
Cc: Brown, Arlene F
Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]

Sent: Wednesday, October 15, 2014 2:36 PM

To: Pope, Kristin (CDC/OID/NCIRD)

Cc: Brown, Arlene F

Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]

Sent: Tuesday, October 14, 2014 6:25 PM

To: Feinberg, Mark

Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)

Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention

Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]

Sent: Tuesday, October 14, 2014 6:12 PM

To: Schuchat, Anne MD (CDC/OID/NCIRD)

Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding "warehousing" of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark

Sent: Thursday, September 18, 2014 3:44 PM

To: Schuchat, Anne MD (CDC/OID/NCIRD)

Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components

of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); WDowdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark; WDowdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fpx9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes

President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact-us.html> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact-us.html> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact-us.html> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact-us.html> that may be confidential,

proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Feinberg, Mark
Sent: 28 Oct 2014 16:22:59 -0400
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Sounds great. Thanks very much (although I have a feeling that I still owe Barb an almond croissant from Alon's).

Should we meet you outside the auditorium where the ACIP meeting will be taking place? If you need to reach me, my cell phone is (b)(6). Please let me know how I can contact you (in case of last minute changes in plans).

We look forward to seeing you.

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [mailto:kfp@cdc.gov]
Sent: Tuesday, October 28, 2014 4:19 PM
To: Feinberg, Mark
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Hi Mark,

10am on Thursday would be better for me if that works for all of you. Thanks, Kristin

From: Feinberg, Mark [mailto:mark.feinberg@merck.com]
Sent: Tuesday, October 28, 2014 4:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well.

I am writing to follow up on our earlier email exchange and to see if you might be able to get together in person this Thursday with me and my colleagues Barb Kuter and Julie McCafferty to discuss how to structure/advance the discussion with Anne, Melinda and other members of the very able CDC team about the pending transition from the 4-valent to 9-valent HPV vaccine. I am sure that your schedule has been as or more complicated as mine of recent, given all the significant and diverse issues the CDC is currently dealing with. If you do have time on Thursday, that would be great. If not, perhaps we can connect again by phone sometime soon. Of potential times on Thursday, might you either be free to get together at 7:30 AM (I would be happy to stop by Alon's and get some breakfast selections!) before the ACIP meeting or potentially at 10 AM (during the typhoid vaccine discussion)? These times would work for me, Barb and Julie.

We look forward to (hopefully) seeing you soon.

Thanks very much,

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp@cdc.gov>]
Sent: Wednesday, October 15, 2014 4:38 PM
To: Feinberg, Mark
Cc: Brown, Arlene F
Subject: RE: Greetings and FollowUp

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Feinberg, Mark [<mailto:mark.feinberg@merck.com>]
Sent: Wednesday, October 15, 2014 2:36 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F
Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent to 9-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mar

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]
Sent: Tuesday, October 14, 2014 6:25 PM

To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the Hilleman lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [<mailto:mark.feinberg@merck.com>]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding “warehousing” of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefully benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with all of the relevant CDC experts, including you and Melinda, to have advance the most complete and shared understanding of the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hillman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like all of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you on line, I am hoping to hear your thoughts about how we might approach having a dialog with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do also think it would be very helpful for you and Melinda hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I also look forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-652-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26 PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <acs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be welcome and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [[mail to: mark.feinberg@merck.com](mailto:mark.feinberg@merck.com)]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC [cdcfoundation.org](mailto:cstokes@cdcfoundation.org)); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); Wdwdle@taskforce.org; King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Hinman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Dana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCC/OCCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very able colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [[mail to: cstokes@cdcfoundation.org](mailto:cstokes@cdcfoundation.org)]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; hinman@taskforce.org; Feinberg, Mark; Wdwdle@taskforce.org; dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Hinman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F; fp9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's lecturer. I will also share with him the list of past lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have an intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Place, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Campaign No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct confidential information for affiliates is available at <http://www.merck.com/confidential/> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct confidential information for affiliates is available at <http://www.merck.com/confidential/> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely

for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml>) that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml>) that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contact.shtml>) that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 28 Oct 2014 20:28:34 +0000
To: 'Feinberg, Mark'
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Sure – I let's meet outside the auditorium and if quiet enough we can grab a table there or we can head to the cafeteria. My cell is 404-433-6121.

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 28, 2014 4:23 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Sounds great. Thanks very much (and I though I have a feeling that I still owe Barbara an almond croissant from Alton's).

Should we meet you outside the auditorium where the ACIP meeting will be taking place? If you need to reach me, my cell phone is (b)(6). Please let me know how I can contact you (in case of last minute changes in plans).

We look forward to seeing you

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [mailto:kfp7@cdc.gov]
Sent: Tuesday, October 28, 2014 4:19 PM
To: Feinberg, Mark
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Hi Mark,

10a.m. Thursday would be better for me if that works for all of you. Thanks, Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 28, 2014 4:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F; Kuter, Barbara J.; McCafferty, Julie Parkinson; Keane, Maggie
Subject: RE: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well.

I am writing to follow up on our earlier email exchange and to see if you might be able to get together in person this Thursday with me and my colleagues Barbara Kuter and Julie McCafferty to discuss how to structure/advance the discussion with Anne, Melinda and other members of the very able CDC team about the pending transition from the 4-valent to 9-valent HPV vaccine. I am sure that your schedule has been a bit more complicated as mine of recent, given all the significant and diverse issues the CDC is currently dealing with. If you do have time on Thursday, that would be great. If not, perhaps we can connect again by phone sometime soon. Of potential times on Thursday, might you either be free to get together at 7:30 AM (I would be happy to stop by Alon's and get some breakfast selections!) before the ACIP meeting or potentially at 10 AM (during the typhoid vaccine discussion)? These times would work for me, Barbara and Julie.

We look forward to (hopefully!) seeing you soon.

Thanks very much,

Best,

Mark

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, October 15, 2014 4:38 PM
To: Feinberg, Mark
Cc: Brown, Arlene F
Subject: RE: Greetings and Follow Up

Sure – happy to talk. If Arlene can send a couple of possible options for a call, we can get it set up. I will be out of the office this Friday and next Monday, but otherwise in the office. Kristin

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Wednesday, October 15, 2014 2:36 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Brown, Arlene F
Subject: FW: Greetings and Follow Up

Dear Kristin,

I hope this note finds you doing very well. I am writing to follow up on Anne's recent note and to see if we might be able to connect by phone sometime soon to discuss how best to arrange/structure a meeting to discuss the broad range of issues related to the impending transition from the 4-valent HPV vaccine (and how this can be approached in a manner that maintains the momentum of the CDC's great ongoing efforts to increase HPV vaccination rates).

My colleague Arlene can help organize a time for us to talk. Is there someone in your office that she can work with to find the best time for you?

Please let me know if you have any questions.

Thanks very much,

Best,

Mark

From: Schuchat, Anne MD (CDC/OID/NCIRD) [<mailto:acs1@cdc.gov>]
Sent: Tuesday, October 14, 2014 6:25 PM
To: Feinberg, Mark
Cc: Pope, Kristin (CDC/OID/NCIRD); Messonnier, Nancy (CDC/OID/NCIRD)
Subject: RE: Greetings and Follow Up

Thanks for following up Mark – will be happy to hear more about the plans on HPV and also take you up on the offer to learn more about the R&D pipeline. For the HPV transition conversation Kristin can probably be best POC to sort out who else to include in the conversations. For the R&D pipeline, Nancy Messonnier, who is our center's new Deputy Director, can be the lead to help arrange a future visit w/ the relevant staff depending on what pipeline topics you'd like to raise. Appreciate the offer and look forward to learning more.

PS – the Hillemann lecture turned out very well – great speaker, turnout, and vibe. We missed you at dinner! Tradition alive and well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Tuesday, October 14, 2014 6:12 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Greetings and Follow Up

Dear Anne,

I hope this note finds you doing very well.

I am writing to follow up on some thoughts included in my earlier note (copied below) regarding the possibility of arranging a meeting with you and members of the broader CDC team you would like to include in a discussion about how best to maintain the momentum of your efforts to increase HPV vaccination rates while avoiding "warehousing" of eligible vaccine recipients as Merck introduces the 9-valent HPV vaccines. As you know, this transition carries a number of potential complexities, and it would be great to hear your thoughts and those of your colleagues about how the best public health outcomes can be achieved as this transition proceeds. Also, I think you may hopefullly benefit from hearing more about the details of our plans as well as the insights that my colleagues have acquired in assessing the parameters and potential complexities of this transition.

Please let me know if you think such a meeting would be valuable to you and the CDC team. While we have had very productive discussions of these issues with a number of your CDC staff, I think it would be great to have a holistic discussion with a lot of the relevant CDC experts, including you and Melinda, to have a chance to most completely understand the plans and associated considerations.

Thanks very much,

Best,

Mark

From: Feinberg, Mark
Sent: Thursday, September 18, 2014 3:44 PM
To: Schuchat, Anne MD (CDC/OID/NCIRD)
Subject: Re: Hilleman Lecture Update

Thanks very much, Anne. I will miss seeing you as well. Hopefully, we will find another time to see each other soon!

Yes, Eddy knows Bill well and, like a lot of us, holds him and his numerous important contributions in high regard. I believe Eddy will be reaching out to you separately to see how to have your and his comments be as complementary as possible.

While I have you online, I am hoping to hear your thoughts about how we might approach having a dialogue with you, Melinda and others at CDC that you would recommend including to discuss the transition from Gardasil to the 9-valent HPV vaccine. We have had very positive and valuable discussions on elements of this topic with a number of CDC staff who have responsibility for different components of the HPV vaccine recommendation and implementation efforts. We do all so think it would be very helpful for you and Melinda to hear an overview of the range (and complexity) of important considerations we will all face in this transition, and about how we can approach it in a holistic manner that maintains (or hopefully even builds) the momentum to increase HPV vaccination rates (which the CDC has done a great job championing). A number of my key colleagues and I would be happy to travel to Atlanta to share information and perspectives with you and your colleagues if you would find it helpful. From our perspective, we believe that there are a number of topics of mutual interest that would be good to review with you. Please let me know what would be most helpful from your perspective.

I am also looking forward to following up on our recent discussion about scheduling a time to review Merck's current vaccine R&D pipeline and share ideas about additional important targets or vaccine delivery enhancements that could improve public health outcomes. Perhaps we can think about having this review sometime later this year.

Thanks very much,

Best,

Mark

Mark Feinberg, MD, PhD
215-662-8664
mark_feinberg@merck.com

On Sep 18, 2014, at 3:26PM, "Schuchat, Anne MD (CDC/OID/NCIRD)" <cs1@cdc.gov> wrote:

We will miss you Mark. I hope things are okay and appreciate your note. Eddy will be well come and great if he has a personal connection with Bill as well.

Anne Schuchat, MD
RADM, US Public Health Service
Assistant Surgeon General
Director, National Center for Immunization and Respiratory Diseases
Mailstop A-27
Centers for Disease Control and Prevention
Atlanta, GA 30333
Phone: 404-639-8200

From: Feinberg, Mark [mailto:mark_feinberg@merck.com]
Sent: Thursday, September 18, 2014 2:53 PM
To: Stokes, Charlie (CDC cdcfoundation.org); Schuchat, Anne MD (CDC/OID/NCIRD); Hinman, Alan (CDC taskforce.org); W.Dowdle@taskforce.org King, Dawn R. (CDC/OID/NCIRD) (CTR); Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra (CDC cdcfoundation.org); Robelotto, Diana (CDC cdcfoundation.org); Brown, Arlene F; Williams, Tara Y. (CDC/OCOO/OCFO) (CTR); King, Dawn R. (CDC/OID/NCIRD) (CTR); Bresnitz, Eddy A.
Subject: RE: Hilleman Lecture Update

Dear Colleagues,

I hope you are all doing well.

I am writing to let you know that due to a just-arising and critical conflicting obligation, I will not be able to travel to Atlanta to participate in this year's Hilleman Lecture event. I will miss seeing all of you and very much miss hearing Bill's lecture. I am sure it will be great.

My very close colleague, Dr. Eddy Bresnitz, has kindly agreed to substitute for in providing introductory remarks as the Merck representative. I believe that many of you know Eddy and he is well known to the public health constituencies in attendance at the meeting. Eddy also knows Bill well, and I like all of us, is a big fan of his. Eddy is copied on this email so that he can be connected to future communications.

I wish you all the best for a very successful event and hope our paths cross another time soon.

Best,

Mark

From: Stokes, Charlie [<mailto:cstokes@cdcfoundation.org>]
Sent: Tuesday, August 26, 2014 6:21 PM
To: acs1@cdc.gov; ahinman@taskforce.org; Feinberg, Mark; W.Dowdle@taskforce.org
dawn.king1@cdc.hhs.gov; Brown, Arlene F
Cc: Honaman, Darlene; Bien-Aime, Sandra; Robelotto, Diana; Brown, Arlene F;
fpx9@cdc.gov; duk3@cdc.gov
Subject: Hilleman Lecture Update
Importance: High

Good afternoon,

Thank you all for your time this morning, I think we accomplished a lot in our short time on the phone.

I have good news to share with you. I called Bill Schaffner this morning and shared with him that the Hilleman Lecture Advisory Committee had met and that he was our unanimous first choice to be this year's Hilleman Lecturer. I apologized for the late notice on the invitation and he completely understood. He shared that he is not only honored to have been chosen, but delighted to accept our invitation. He would like to thank the advisory committee for all of your time and in selecting him for this important work.

Attached is the letter I will send to Bill officially inviting him to serve as this year's Lecturer. I will also share with him the list of past Lecturers. I thank you for your support of this important lectureship. With Bill's acceptance, I believe we are set up to have a n intriguing and worthwhile event.

Many thanks,

Charlie

Charlie Stokes
President and CEO

CDC Foundation
55 Park Plaza, Suite 400 :: Atlanta, GA 30303
404.523-3580 :: 404.653.0330 fax :: www.cdcfoundation.org

***Building innovative partnerships to
advance CDC's 24/7 life-saving work
to protect us all***

Combined Federal Acquisition No. 10141

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct confidential information for affiliates is available at <http://www.merck.com/ncat/ncat.s.htm> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are

no t t he int ended redipient , and have received t his message in erro r,
please no t ify us immediat ely by reply e-mail and t hen delet e it fro m
yo ur syst em.

Not ice: This e-mail message, t o get her wit h any at t achment s, co nt ains
info rmat io n o f Merck & Co ., Inc (One Merck Drive, Whit eho use St at io n,
New Jersey, USA 08889), and/o r it s affiliat es Direct co nt act info rmat io n
fo r affiliat es is available at
[ht t p: //www.merck.co m/co nt act /co nt act s.ht](http://www.merck.com/cont act /cont act s.htm) that may be co nfident ial,
pro priet ary co pyright ed and/o r legally privileged. It is int ended so lely
fo r t he use o f t he individual o r ent it y named o n t his message. If yo u are
no t t he int ended redipient , and have received t his message in erro r,
please no t ify us immediat ely by reply e-mail and t hen delet e it fro m
yo ur syst em.

Not ice: This e-mail message, t o get her wit h any at t achment s, co nt ains
info rmat io n o f Merck & Co ., Inc (One Merck Drive, Whit eho use St at io n,
New Jersey, USA 08889), and/o r it s affiliat es Direct co nt act info rmat io n
fo r affiliat es is available at
[ht t p: //www.merck.co m/co nt act /co nt act s.ht](http://www.merck.com/cont act /cont act s.htm) that may be co nfident ial,
pro priet ary co pyright ed and/o r legally privileged. It is int ended so lely
fo r t he use o f t he individual o r ent it y named o n t his message. If yo u are
no t t he int ended redipient , and have received t his message in erro r,
please no t ify us immediat ely by reply e-mail and t hen delet e it fro m
yo ur syst em.

Not ice: This e-mail message, t o get her wit h any at t achment s, co nt ains
info rmat io n o f Merck & Co ., Inc (One Merck Drive, Whit eho use St at io n,
New Jersey, USA 08889), and/o r it s affiliat es Direct co nt act info rmat io n
fo r affiliat es is available at
[ht t p: //www.merck.co m/co nt act /co nt act s.ht](http://www.merck.com/cont act /cont act s.htm) that may be co nfident ial,
pro priet ary co pyright ed and/o r legally privileged. It is int ended so lely
fo r t he use o f t he individual o r ent it y named o n t his message. If yo u are
no t t he int ended redipient , and have received t his message in erro r,
please no t ify us immediat ely by reply e-mail and t hen delet e it fro m
yo ur syst em.

Not ice: This e-mail message, t o get her wit h any at t achment s, co nt ains
info rmat io n o f Merck & Co ., Inc (One Merck Drive, Whit eho use St at io n,
New Jersey, USA 08889), and/o r it s affiliat es Direct co nt act info rmat io n
fo r affiliat es is available at
[ht t p: //www.merck.co m/co nt act /co nt act s.ht](http://www.merck.com/cont act /cont act s.htm) that may be co nfident ial,
pro priet ary co pyright ed and/o r legally privileged. It is int ended so lely
fo r t he use o f t he individual o r ent it y named o n t his message. If yo u are
no t t he int ended redipient , and have received t his message in erro r,
please no t ify us immediat ely by reply e-mail and t hen delet e it fro m
yo ur syst em.

From: Bridges, Carolyn (CDC/OID/NCIRD)
Sent: 10 Apr 2014 08:45:04 -0400
To: 'eddy_bresnitz@merck.com'; Hales, Craig (CDC/OID/NCIRD); Harpaz, Rafael (CDC/OID/NCIRD); Gold, Rebecca (CDC/OID/NCIRD); Pope, Kristin (CDC/OID/NCIRD)
Subject: Re: HHS announces progress in disease prevention and health promotion

Thanks for your email, Eddy. Copying Rebecca Gold and Kristin Pope also for their information.

From: Bresnitz, Eddy A. [mailto:eddy_bresnitz@merck.com]
Sent: Tuesday, April 08, 2014 10:06 AM Eastern Standard Time
To: Hales, Craig (CDC/OID/NCIRD); Harpaz, Rafael (CDC/OID/NCIRD); Bridges, Carolyn (CDC/OID/NCIRD)
Subject: FW: HHS announces progress in disease prevention and health promotion

Craig/Rafael/Carolyn: Although not in this report, HZ vaccination rates have made great progress and should make HP2020 target by sometime in 2014, any chance of raising the target this year to a higher level, say 60%? Thanks for your consideration. Eddy

From: HHS News [mailto:donotreply@subscriptions.hhs.gov]
Sent: Tuesday, April 08, 2014 9:48 AM
To: Bresnitz, Eddy A.
Subject: HHS announces progress in disease prevention and health promotion



[HHS announces progress in disease prevention and health promotion](#)

The nation's health is improving in more than half of the critical measures that are known to have major influence in reducing preventable disease and death, according to a new [report](#) from the U.S. Department of Health and Human Services.

Read [more about today's announcement](#).

SHARE THIS

You are subscribed to HHS News Releases from the U.S. Department of Health & Human Services. Having trouble viewing this email? [View it as a Web page.](#)

All HHS News Releases are available in the [HHS Newsroom](#). Visit the [HHS Multimedia Gallery](#).

--

[Preferences](#) | [Unsubscribe](#) | [Contact HHS](#)



This email was sent to eddy_bresnitz@merck.com using GovDelivery, on behalf of the U.S. Dept. of Health & Human Services · 200 Independence Avenue SW · Washington DC 20201 · 1-877-696-6775



Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 10 Nov 2014 23:53:35 +0000
To: 'barbara_kuter@merck.com'
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: Re: Meeting with NCIRD

It would probably be simpler to do a phone conference, especially with the potential changes in Anne's schedule.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Monday, November 10, 2014 06:31 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: RE: Meeting with NCIRD

Kristin,

Nov 24 is not a good date for us – just because so many are on vacation that week since it is a holiday week. I will check on Dec 8. Would you like us to come to CDC or should we plan on a video or teleconference?

Thanks.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [mailto:kfp7@cdc.gov]
Sent: Monday, November 10, 2014 5:11 PM
To: Kuter, Barbara J.
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: Meeting with NCIRD

Hi Barb,

It was good talking with you and your group last week about scheduling a meeting with Merck and NCIRD leadership to discuss the HPV9 transition. I have a few dates to offer below, and as we discussed last week, we can schedule additional meetings with program staff and others as your schedule allows. I am sure you understand that Anne's schedule is a bit in flux. These dates look good for her now, but things are a bit dynamic and could change. But we have to start somewhere, so please let me know if either of these work for you. Yours, Kristin

Monday, Nov. 24th 3-4pm

Monday Dec. 8th 3-4pm

Kristin Pope, M.Ed.

Associate Director for Policy

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

Kfp7@cdc.gov

Office: 404-639-8714

Cell: 404-433-6121

Teleworking Tuesdays and Thursdays

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Thompson, Natarsha (CDC/OID/NCIRD)
Sent: 12 Nov 2014 12:33:59 -0500
To: Kuter, Barbara J.;Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD);King, Dawn R. (CDC/OID/NCIRD) (CTR)
Subject: RE: Meeting with NCIRD

Hi Barbara,

Dr. Schuchat's schedule at this time is a bit of a challenge, and therefore she only has an hour. Will the Monday, Dec. 8 3:00-4:00 work?

Thanks,
Natarsha

Natarsha L. Thompson, MPH, CHES
Special Assistant to the Director, NCIRD
Phone: 404-639-8037
BB: 404-323-7787
Email: natarsha.thompson@cdc.hhs.gov

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 12, 2014 12:19 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: RE: Meeting with NCIRD

Kristin,

One more thought. Based on the agenda under consideration, it is probably going to be hard to cover everything in one hour. Might we consider a 2 hour time slot?

Thanks for considering.

Barb

From: Kuter, Barbara J.
Sent: Monday, November 10, 2014 6:31 PM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: RE: Meeting with NCIRD

Kristin,

Nov 24 is not a good date for us – just because so many are on vacation that week since it is a holiday week. I will check on Dec 8. Would you like us to come to CDC or should we plan on a video or teleconference?

Thanks.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Monday, November 10, 2014 5:11 PM
To: Kuter, Barbara J.
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: Meeting with NCIRD

Hi Barb,

It was good talking with you and your group last week about scheduling a meeting with Merck and NCIRD leadership to discuss the HPV9 transition. I have a few dates to offer below, and as we discussed last week, we can schedule additional meetings with program staff and others as your schedule allows. I am sure you understand that Anne's schedule is a bit in flux. These dates look good for her now, but things are a bit dynamic and could change. But we have to start somewhere, so please let me know if either of these work for you. Yours, Kristin

Monday, Nov. 24th 3-4pm

Monday Dec. 8th 3-4pm

Kristin Pope, M.Ed.

Associate Director for Policy
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
kfp7@cdc.gov
Office: 404-639-8714
Cell: 404-433-6121

Teleworking Tuesdays and Thursdays

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at http://www.merck.com/contact/contact_us.htm that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 18 Nov 2014 13:53:28 +0000
To: 'barbara_kuter@merck.com'
Subject: Re: Meeting with NCIRD

Hi Barb,

Let me know what would be a good time for us to chat this week.

Kristin
Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 12, 2014 04:51 PM
To: Thompson, Natarsha (CDC/OID/NCIRD); Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD); King, Dawn R. (CDC/OID/NCIRD) (CTR)
Subject: RE: Meeting with NCIRD

I have checked with the team here and we can meet on Dec 8 from 3-4 pm. Is a videoconference possible?

Kristin- let's work on the agenda, especially with our limited time. Perhaps we can talk early next week?
My number is (b)(6)

Thanks.

Barb

From: Thompson, Natarsha (CDC/OID/NCIRD) [mailto:nct8@cdc.gov]
Sent: Wednesday, November 12, 2014 12:34 PM
To: Kuter, Barbara J.; Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD); King, Dawn R. (CDC/OID/NCIRD) (CTR)
Subject: RE: Meeting with NCIRD

Hi Barbara,

Dr. Schuchat's schedule at this time is a bit of a challenge, and therefore she only has an hour. Will the Monday, Dec. 8 3:00-4:00 work?

Thanks,
Natarsha

Natarsha L. Thompson, MPH, CHES
Special Assistant to the Director, NCIRD
Phone: 404-639-8037
BB: 404-323-7787

Email: natarsha.thompson@cdc.hhs.gov

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 12, 2014 12:19 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: RE: Meeting with NCIRD

Kristin,

One more thought. Based on the agenda under consideration, it is probably going to be hard to cover everything in one hour. Might we consider a 2 hour time slot?

Thanks for considering.

Barb

From: Kuter, Barbara J.
Sent: Monday, November 10, 2014 6:31 PM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: RE: Meeting with NCIRD

Kristin,

Nov 24 is not a good date for us – just because so many are on vacation that week since it is a holiday week. I will check on Dec 8. Would you like us to come to CDC or should we plan on a video or teleconference?

Thanks.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Monday, November 10, 2014 5:11 PM
To: Kuter, Barbara J.
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: Meeting with NCIRD

Hi Barb,

It was good talking with you and your group last week about scheduling a meeting with Merck and NCIRD leadership to discuss the HPV9 transition. I have a few dates to offer below, and as we discussed last week, we can schedule additional meetings with program staff and others as your schedule allows. I am sure you understand that Anne's schedule is a bit in flux. These dates look good for her now, but

things are a bit dynamic and could change. But we have to start somewhere, so please let me know if either of these work for you. Yours, Kristin

Monday, Nov. 24th 3-4pm

Monday Dec. 8th 3-4pm

Kristin Pope, M.Ed.

Associate Director for Policy

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

Kfp7@cdc.gov

Office: 404-639-8714

Cell: 404-433-6121

Teleworking Tuesdays and Thursdays

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html> that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 18 Nov 2014 13:57:17 +0000
To: 'barbara_kuter@merck.com'
Subject: Re: Meeting with NCIRD

9:30am would be perfect.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Tuesday, November 18, 2014 08:55 AM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Meeting with NCIRD

Hi,

How about Weds at 9:30 or 4:30?

Thanks.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Tuesday, November 18, 2014 8:53 AM
To: Kuter, Barbara J.
Subject: Re: Meeting with NCIRD

Hi Barb,

Let me know what would be a good time for us to chat this week.

Kristin
Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 12, 2014 04:51 PM
To: Thompson, Natarsha (CDC/OID/NCIRD); Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD); King, Dawn R. (CDC/OID/NCIRD) (CTR)
Subject: RE: Meeting with NCIRD

I have checked with the team here and we can meet on Dec 8 from 3-4 pm. Is a videoconference possible?

Kristin- let's work on the agenda, especially with our limited time. Perhaps we can talk early next week?
My number is (b)(6)

Thanks.

Barb

From: Thompson, Natarsha (CDC/OID/NCIRD) [<mailto:nct8@cdc.gov>]
Sent: Wednesday, November 12, 2014 12:34 PM
To: Kuter, Barbara J.; Pope, Kristin (CDC/OID/NCIRD)
Cc: Swartwood, Candice (CDC/OID/NCIRD); King, Dawn R. (CDC/OID/NCIRD) (CTR)
Subject: RE: Meeting with NCIRD

Hi Barbara,

Dr. Schuchat's schedule at this time is a bit of a challenge, and therefore she only has an hour. Will the Monday, Dec. 8 3:00-4:00 work?

Thanks,
Natarsha

Natarsha L. Thompson, MPH, CHES
Special Assistant to the Director, NCIRD
Phone: 404-639-8037
BB: 404-323-7787
Email: natarsha.thompson@cdc.hhs.gov

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 12, 2014 12:19 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: RE: Meeting with NCIRD

Kristin,

One more thought. Based on the agenda under consideration, it is probably going to be hard to cover everything in one hour. Might we consider a 2 hour time slot?

Thanks for considering.

Barb

From: Kuter, Barbara J.
Sent: Monday, November 10, 2014 6:31 PM

To: 'Pope, Kristin (CDC/OID/NCIRD)'
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: RE: Meeting with NCIRD

Kristin,

Nov 24 is not a good date for us – just because so many are on vacation that week since it is a holiday week. I will check on Dec 8. Would you like us to come to CDC or should we plan on a video or teleconference?

Thanks.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Monday, November 10, 2014 5:11 PM
To: Kuter, Barbara J.
Cc: Thompson, Natarsha (CDC/OID/NCIRD)
Subject: Meeting with NCIRD

Hi Barb,

It was good talking with you and your group last week about scheduling a meeting with Merck and NCIRD leadership to discuss the HPV9 transition. I have a few dates to offer below, and as we discussed last week, we can schedule additional meetings with program staff and others as your schedule allows. I am sure you understand that Anne's schedule is a bit in flux. These dates look good for her now, but things are a bit dynamic and could change. But we have to start somewhere, so please let me know if either of these work for you. Yours, Kristin

Monday, Nov. 24th 3-4pm

Monday Dec. 8th 3-4pm

Kristin Pope, M.Ed.
Associate Director for Policy
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
kfp7@cdc.gov
Office: 404-639-8714
Cell: 404-433-6121

Teleworking Tuesdays and Thursdays

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information

for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 20 Nov 2014 00:04:55 +0000
To: 'barbara_kuter@merck.com'
Subject: Re: Proposed Agenda - Dec 8 CDC/Merck Meeting

Sure, I will send you an updated org chart tomorrow.

We do have a scheduling problem now as I just learned Anne is going to be out of the country December 8th. I am checking on other dates/times and will get back with you as soon as possible.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 05:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

One more thing. I realize that some of the CDC folks who will be on this call on Dec 8 are in new positions. Is there an updated set of org charts showing who now does what, please? I did not see an update on the CDC website.

Thanks.

Barb

From: Kuter, Barbara J.
Sent: Wednesday, November 19, 2014 9:26 AM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Subject: Proposed Agenda - Dec 8 CDC/Merck Meeting

Hi Kristin,

Here is a draft agenda that we can discuss on our call this morning.

I will talk with you in 5 minutes!

Barb

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information

for affiliates is available at
<http://www.merck.com/contact/contacts.html>) that may be confidential,
proprietary copyrighted and/or legally privileged. It is intended solely
for the use of the individual or entity named on this message. If you are
not the intended recipient, and have received this message in error,
please notify us immediately by reply e-mail and then delete it from
your system.

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 20 Nov 2014 18:56:30 +0000
To: 'Kuter, Barbara J.'
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting
Attachments: NCIRDOrgChart_May2014.pptx

Attached is the most recent NCIRD org chart. Let me know if you have any questions.

I know this option isn't ideal, but would either of these work for your group?

Monday, December 15th – 11am- 12pm or 4-5pm

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 8:29 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Thanks for the heads up re the date.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, November 19, 2014 7:05 PM
To: Kuter, Barbara J.
Subject: Re: Proposed Agenda - Dec 8 CDC/Merck Meeting

Sure, I will send you an updated org chart tomorrow.

We do have a scheduling problem now as I just learned Anne is going to be out of the country December 8th. I am checking on other dates/times and will get back with you as soon as possible.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 05:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

One more thing. I realize that some of the CDC folks who will be on this call on Dec 8 are in new positions. Is there an updated set of org charts showing who now does what, please? I did not see an update on the CDC website.

Thanks.

Barb

From: Kuter, Barbara J.
Sent: Wednesday, November 19, 2014 9:26 AM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Subject: Proposed Agenda - Dec 8 CDC/Merck Meeting

Hi Kristin,

Here is a draft agenda that we can discuss on our call this morning.


I will talk with you in 5 minutes!

Barb

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html> that may be confidential, proprietary, copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

NCIRD Organizational Structure



*Acting



Updated: November 20, 2014

From: Pope, Kristin (CDC/OID/NCIRD)
Sent: 21 Nov 2014 17:57:19 +0000
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

I think Anne should be back in the office on 12/15, so either time should work.

This is the earliest date she has available, and hopefully there won't be any further glitches!

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Friday, November 21, 2014 12:20 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

Thanks for the org chart – very helpful.

I am sure we can figure out how to make Dec 15 work. Please give me a day or so to see which time is better at this end. Do you think 4-5 might be better for Anne?

And I will ask the obvious – I assume there is no way we can talk during the first week of December, correct?

Thanks again!

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Thursday, November 20, 2014 1:57 PM
To: Kuter, Barbara J.
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Attached is the most recent NCIRD org chart. Let me know if you have any questions.

I know this option isn't ideal, but would either of these work for your group?

Monday, December 15th – 11am- 12pm or 4-5pm

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 8:29 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Thanks for the heads up re the date.

Barb

From: Pope, Kristin (CDC/OID/NCIRD) [<mailto:kfp7@cdc.gov>]
Sent: Wednesday, November 19, 2014 7:05 PM
To: Kuter, Barbara J.
Subject: Re: Proposed Agenda - Dec 8 CDC/Merck Meeting

Sure, I will send you an updated org chart tomorrow.

We do have a scheduling problem now as I just learned Anne is going to be out of the country December 8th. I am checking on other dates/times and will get back with you as soon as possible.

Kristin Pope
NCIRD, CDC
Office: 404-639-8714
Cell: 404-433-6121

From: Kuter, Barbara J. [mailto:barbara_kuter@merck.com]
Sent: Wednesday, November 19, 2014 05:15 PM
To: Pope, Kristin (CDC/OID/NCIRD)
Subject: RE: Proposed Agenda - Dec 8 CDC/Merck Meeting

Kristin,

One more thing. I realize that some of the CDC folks who will be on this call on Dec 8 are in new positions. Is there an updated set of org charts showing who now does what, please? I did not see an update on the CDC website.

Thanks.

Barb

From: Kuter, Barbara J.
Sent: Wednesday, November 19, 2014 9:26 AM
To: 'Pope, Kristin (CDC/OID/NCIRD)'
Subject: Proposed Agenda - Dec 8 CDC/Merck Meeting

Hi Kristin,

Here is a draft agenda that we can discuss on our call this morning.

I will talk with you in 5 minutes!

Barb

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information

for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates. Direct contact information for affiliates is available at

<http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.